ALDX

Business Context and Reporting Period

Company: Aldeyra Therapeutics, Inc. (ALDX)
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal year ended December 31, 2025
Business Overview: Aldeyra is a clinical-stage biotechnology company developing RASP (reactive aldehyde species) modulators for immune-mediated diseases. The company has no approved products and generates no product revenue. Its primary focus is the late-stage development of reproxalap (for dry eye disease and allergic conjunctivitis) and ADX-2191 (for primary vitreoretinal lymphoma and retinitis pigmentosa). As of December 31, 2025, the company had 8 full-time employees.

Key Financial Metrics

Note: The company reported no revenue for either period. The decrease in net loss in 2025 was primarily driven by a significant reduction in R&D expenses.

Material Changes vs. Prior Period

• Reduced Burn Rate: Net loss decreased by approximately 39.4% (from $55.9M to $33.8M). R&D expenses dropped by 46.8% ($22.5M decrease), attributed to lower external clinical development costs, reduced drug manufacturing costs, and decreased personnel and consulting expenditures.
• Cash Position: Cash and cash equivalents increased by $15.5 million to $70.0 million, despite operating cash outflows of $33.3 million. This increase was driven by net cash provided by investing activities ($47.7 million) due to the maturity of marketable securities.
• Debt Structure: The Hercules Credit Facility ($15.0 million outstanding) was amended in 2024 to extend the maturity date to April 1, 2026, with interest-only payments required until that date. The effective interest rate was 12.4% as of year-end 2025.
• Regulatory Status: The company received a Complete Response Letter (CRL) from the FDA in April 2025 regarding its second NDA resubmission for reproxalap. Following a successful second chamber trial (May 2025), the company resubmitted the NDA in June 2025. In December 2025, the FDA requested the inclusion of a field trial, extending the PDUFA target action date to March 16, 2026.

Guidance, Outlook, and Risks

Outlook and Capital Needs: Management believes cash resources of $70.0 million are sufficient to fund operations and debt obligations for at least 12 months from February 27, 2026. The company anticipates needing substantial additional financing in the future to fund commercialization efforts if reproxalap is approved, or to continue development if the AbbVie option is not exercised. No sales have been made under the $75.0 million Jefferies Sales Agreement as of year-end.

Strategic Partnership (AbbVie): Aldeyra holds an exclusive option agreement with AbbVie Inc. regarding reproxalap. AbbVie has paid $6.0 million in non-refundable fees ($1.0M option payment + $5.0M extension fee). If AbbVie exercises the option (which expires 10 business days after FDA approval), Aldeyra would receive a $100.0 million upfront payment (net of fees) and up to $300.0 million in milestones. As of February 27, 2026, AbbVie has not exercised the option.

Key Risks and Contingencies:

• Regulatory Uncertainty: Approval of reproxalap is not guaranteed. The FDA has previously issued CRLs citing insufficient efficacy data. The current PDUFA date is March 16, 2026.
• Liquidity Risk: The company has incurred significant losses since inception and expects to continue doing so. Failure to secure additional capital could force delays or termination of development programs.
• Manufacturing: The company relies entirely on third-party contract manufacturers. An FDA inspection in August 2025 identified deficiencies at the reproxalap manufacturer, though the facility was closed with a "Voluntary Action Indicated" (VAI) classification and no further action deemed necessary at that time.
• Dependence on AbbVie: If AbbVie does not exercise its option, Aldeyra will be solely responsible for funding commercialization, which requires significant capital and infrastructure not currently in place.

Investor Verification Checklist

• Reproxalap NDA Status: Verify the final FDA decision on the reproxalap NDA resubmission, expected by March 16, 2026, and whether the field trial data was accepted.
• AbbVie Option Exercise: Monitor for a public announcement regarding whether AbbVie exercises its option within 10 business days of FDA approval (if granted).
• Cash Runway: Confirm the company's ability to fund operations through the first quarter of 2027 without additional dilutive equity or debt financing.
• Manufacturing Compliance: Review any subsequent FDA communications regarding the third-party manufacturer's remediation plan and future inspection status.
• ADX-2191 Progress: Track the initiation of the Phase 2/3 clinical trial for retinitis pigmentosa, planned for the first half of 2026.